- Novo Nordisk’s growth in the pharmaceutical market is significantly driven by its GLP-1 drugs, Wegovy and Ozempic, which generated 63.25 billion Danish Krone in Q1 2026, comprising nearly 65% of total quarterly revenues.
- Despite maintaining a Neutral rating, Citigroup (NYSE:C) increased its price target for Novo Nordisk (NYSE:NVO) stock to DKK 290 from DKK 275, indicating a mixed investment outlook.
- While Novo Nordisk has shown strong recent performance with its stock rising over 21%, Citigroup remains cautious due to potential “portfolio price erosion and long-term competition” from rivals like Eli Lilly (NYSE:LLY) in the diabetes and obesity treatment space.
Novo Nordisk (NYSE:NVO) is a global pharmaceutical company specializing in diabetes and obesity treatments. Its growth is powered by its innovative GLP-1 drugs, including the popular Wegovy and Ozempic. The company operates in a highly competitive market, with its main rival being Eli Lilly (NYSE:LLY), which also develops drugs for diabetes and obesity.
On May 12, 2026, the analyst firm Citigroup (NYSE:C) maintained its Neutral rating on Novo Nordisk with a Hold action. Despite the cautious rating, Citigroup increased its price target for the company’s stock to DKK 290 from DKK 275. A price target is an analyst’s projection of a stock’s future price, offering insight into potential stock performance.
The price target increase follows a period of strong performance for Novo Nordisk. The company’s stock has risen over 21% in the past month, driven by first-quarter 2026 results that were better than expected. Its GLP-1 drugs, Wegovy and Ozempic, generated 63.25 billion Danish Krone, making up nearly 65% of total quarterly revenues, highlighting their significant contribution to pharmaceutical sales.
However, Citigroup’s Neutral rating reflects concerns about the company’s future investment outlook. As highlighted by Proactive Investors, the bank is cautious due to potential “portfolio price erosion and long-term competition.” This means they are worried about falling drug prices and increased pressure from competitors like Eli Lilly over time in the evolving GLP-1 market.
This mixed view is also seen in Citigroup’s detailed forecasts. While they raised their 2026 sales estimate for the Wegovy pill to $2.70 billion, they also cut their overall 2026 sales estimate for Novo Nordisk by 4%. This suggests confidence in a specific product but caution about the company’s total performance and future revenue growth.
